Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol ...

Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent ...

BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer ...

Nuvalent, a US biopharma developing precisely targeted therapies for clinically-proven kinase targets in cancer, has ...

In a Phase I/II clinical trial, TKI-pretreated NSCLC patients given zidesamtinib had an overall response rate of 44 percent.

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung ...

Nuvalent's promising trial results for zidesamtinib show a 44%-51% response rate in ROS1-positive lung cancer. Read more here ...

In 117 ROS1 TKI pre-treated patients, including 50% who had received = 2 prior ROS1 TKIs ± chemotherapy, ORR by BICR was 44% (95% CI: 34, 53) with initial estimated durability of response of 78% ...

Cambridge, Massachusetts-based Nuvalent has reported the results of its phase 1/2 ARROS-1 trial of zidesamtinib in previously ...